Tirzepatide clinical trials near me: what the research showed and how to access treatment today

Step 1, Understand what the trials actually found

The SURMOUNT programme is where the evidence for tirzepatide's use in weight management was built. SURMOUNT-1, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity or overweight plus at least one weight-related condition. Over 72 weeks, participants at the 15mg dose achieved an average body-weight reduction of around 20–21%, a figure that had not been reached by any previously licensed weight-loss medicine.

Then came the head-to-head data. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, 751 adults with obesity and no diabetes were assigned to either tirzepatide or semaglutide 2.4mg for 72 weeks. Tirzepatide produced greater average weight loss. That trial is the reason NICE referenced indirect comparisons favouring tirzepatide when it published its guidance in December 2024.

The full history of Eli Lilly's tirzepatide trial programme spans both the SURMOUNT (weight management) and SURPASS (type 2 diabetes) series, involving well over 10,000 participants across the combined programmes. What matters for you, practically, is that recruitment closed years ago. The science is done. The question now is how to access treatment.

Step 2, Know what 'near me' actually means post-trial

Trial sites are research facilities, often linked to university hospitals, that recruit participants during a medicine's development phase. Once a medicine is licensed, those same hospitals treat patients through normal clinical pathways, not trial enrolment. There is no tirzepatide trial currently recruiting near you for weight management in the general UK adult population; that phase is over.

What does exist near you is access via two routes: NHS prescription or private prescription. The NHS route is governed by NICE guidance (TA1026, updated September 2025), which recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, within a phased rollout through primary care and specialist services. Depending on where you live and which cohort you fall into, that route may involve a significant wait. If you want to understand the NHS phases in more detail, the NHS rollout context page sets them out clearly.

Private prescription is the other route, legal, regulated, and available now. A GPhC-registered prescriber assesses your medical history, weight, and circumstances, then decides whether tirzepatide is clinically appropriate for you. No trial site, no referral letter, no waiting list at a research centre.

Step 3, Understand what private prescription access looks like in practice

Private treatment through a regulated online pharmacy is straightforward if you choose a legitimate provider. The process at nume runs like this: you complete a free medical consultation, a GPhC-registered Independent Prescriber reads your answers the same day (a real clinician, not an automated system), and if you're clinically suitable your treatment is dispatched the same working day if you ordered before midday, arriving with DPD the next working day in plain packaging.

If you'd like to compare what different private providers charge, the Mounjaro price comparison page gives an honest breakdown of what market pricing looks like since Eli Lilly adjusted the UK list price in September 2025. One thing worth knowing: a legitimate private prescription always includes clinical assessment. Any listing that sidesteps that is a red flag, not a deal.

For those unsure whether a private clinic or an online pharmacy suits them better, it helps to read about tirzepatide clinics near you before deciding. The medicine is the same regardless of route; the clinical oversight and support model differ.

Practical note on storage: once your pen arrives, it lives in the fridge, the 2–8°C compartment rather than the door, where temperatures can fluctuate. The Patient Information Leaflet that comes with each pen gives the exact room-temperature window for if you need to travel; always check it rather than relying on a general figure.

Step 4, Check eligibility before you book anything

Tirzepatide is licensed privately for adults with a BMI of 30 or above, or 27 or above if you have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower thresholds of 2.5 kg/m² apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance.

A BMI figure alone doesn't guarantee a prescription. Your prescriber considers the full picture, your medical history, any medicines you currently take, and conditions that would make tirzepatide unsuitable. The medicine isn't licensed for use during pregnancy, breastfeeding, or when trying to conceive, and it isn't approved for under-18s. The NHS tirzepatide page sets out the main contraindications in plain language if you want to read ahead.

If you want to understand the broader treatment landscape, the weight-loss treatment overview covers all the options currently available. And if you're ready to find out whether tirzepatide is right for you specifically, choosing where to buy Mounjaro is itself a question worth thinking through carefully, before a consultation is where that question gets answered, by a prescriber, not a webpage.